ClinicalTrials.gg
CompletedNCT07801326Updated Sep 3, 2026

A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants

A Phase 1 interventional study of MWN109 Tablets in Type 2 Diabetes Mellitus (T2DM) and Overweight , Obesity, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2026, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
410th of 767
162 · median 199
Started
2026
with 87 others
Phase 1
122 of 909
12 open now
Registered
879th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 410th largest by enrollment of the 767 interventional ones that give a count, is one of 88 that started in 2026, is one of 122 in phase 1, and was the 879th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This is a randomized, open-label, multiple-dose study to evaluate the effects of different volumes of administration water, post-dose fasting duration, and high-fat diet on the pharmacokinetics of the 15 mg dose of MWN109 tablets in adult Chinese participants, as well as to assess its safety, tolerability, and immunogenicity.

The study consists of two parts. Part 1 is an administration condition study, which includes 6 groups stratified by post-dose fasting duration and administration water volume. Part 2 is a food-effect study, comprising 3 groups stratified by dietary conditions..

A total of 162 participants are planned to be enrolled. The primary endpoint is pharmacokinetics (PK). PK parameters include Cmax, Cmin, AUC0-t, AUC0-∞, Tmax, and t1/2. Secondary endpoints include safety (adverse events [AEs] and serious adverse events [SAEs]) and immunogenicity (anti-drug antibodies [ADAs]).

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Overweight , Obesity
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 to 50 years, inclusive, at the time of signing the form.
  2. (BMI) = weight (kg) / height squared (m²): 19.0 kg/m² ≤ BMI \< 30.0 kg/m², with a body weight ≥ 55 kg for males or ≥ 50 kg for females.

Exclusion criteria

Exclusion Criteria:

  1. History of severe drug allergy (especially known or suspected allergy to any component or of MWN109 tablets), severe atopic allergic disease/history (e.g., asthma, urticaria, eczematous dermatitis), or a severe allergic constitution.
  2. History of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury, or other high-risk factors that may lead to pancreatitis.
  3. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; history of thyroid insufficiency or abnormal thyroid hormone levels.
  4. Gastrointestinal diseases at present or at screening that may increase participant risk, such as abnormal gastric emptying (e.g., gastroparesis, pyloric stenosis, pyloric obstruction), severe chronic gastrointestinal diseases (e.g., history of intestinal obstruction, active ulcer within 6 months), previous gastric resection surgery, or gastrointestinal clinical symptoms or signs at screening (e.g., diarrhea, constipation, nausea, vomiting, irregular bowel movements, or alternating diarrhea and constipation) (diarrhea is defined as watery stools and/or ≥ 3 bowel movements per day; constipation is defined as the inability to achieve a bowel movement at least every other day).
  5. History of any of the following cardiac diseases within 6 months prior to screening: decompensated cardiac insufficiency ( [NYHA] class III or IV); unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation.
  6. Hemorrhagic or ischemic stroke within 6 months prior to screening, if judged by the investigator to be unsuitable for participation in this clinical trial.
  7. Severe hypoglycemia or recurrent symptomatic hypoglycemia (≥ 2 episodes within 6 months) within 6 months prior to screening (e.g., anxiety, dizziness, sweating, tremor, hunger, and poor concentration).
  8. Any laboratory finding at screening meeting any of the following criteria:

    1. (HbA1c) ≥ 6.5%, or fasting blood glucose (GLU) > 6.1 mmol/L or \< 3.9 mmol/L.
    2. (ALT), aspartate aminotransferase (AST), or total (TBIL) > 1.5 times the (ULN).
    3. serum creatinine (CR) > 1.1 times ULN, or estimated (eGFR) \< 80 mL/min/1.73 m2 (CKD-EPI formula), or urine protein (PRO) positive (1+) or above.
    4. serum uric acid (UA) > 540 μmol/L.
    5. serum calcitonin (PCT) ≥ 35 ng/L.
    6. thyroid-stimulating hormone (TSH) > 6.0 mIU/L or below the lower limit of normal (LLN).
    7. fasting triglycerides (TG) ≥ 3.42 mmol/L.
    8. amylase (AMY) > 1.5 times ULN.
    9. (HGB) \< 100 g/L (female) or \< 110 g/L (male).
    10. positive for surface antigen (HBsAg), virus antibody (HCV-Ab), antibody (HIV-Ab), or Treponema pallidum antibody (TPAb).
    11. 12-lead (ECG) showing heart rate \< 50 beats/min or > 90 beats/min, second- or third-degree atrioventricular block, long syndrome, or QTcF > 470 ms (female) or > 450 ms (male), or other ECG abnormalities judged by the investigator to require drug intervention.
    12. positive urine drug abuse screening.
    13. positive alcohol breath test.
  9. Participation in any drug or medical device clinical trial and receipt of drug or medical device intervention within 3 months prior to screening.
  10. Use of any prescription or over-the-counter medication (including chemical drugs, vitamins, herbal medicines, etc.) within 2 weeks prior to dosing.
  11. Smoking more than 10 cigarettes per day (including nicotine replacement products) within 3 months prior to screening, or inability to refrain from smoking during the confinement period.
  12. Regular alcohol consumption within 3 months prior to screening, i.e., average weekly alcohol intake greater than 14 units of alcohol (1 unit = 17.7 mL of ethanol, i.e., 1 unit = 357 mL of beer with 5% alcohol, or 43 mL of liquor with 40% alcohol, or 147 mL of wine with 12% alcohol), or inability to abstain from alcohol during the trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants receive oral MWN109 tablets under varying conditions of administration water volume and post-dose feeding time.

    Drug: MWN109 Tablets

  • Experimental
    Part 2

    Participants take oral MWN109 tablets under three conditions: fasted state, fed state, or feeding after drug administration.

    Drug: MWN109 Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of MWN109.

    Time frame: From Day 1 to Day 29

  2. Minimum Concentration (Cmin)

    Cmin of MWN109.

    Time frame: From Day 1 to Day 29

  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

    AUC0-t of MWN109.

    Time frame: From Day 1 to Day 29

  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)

    AUC0-inf of MWN109.

    Time frame: From Day 1 to Day 29

  5. Time to Reach Maximum Concentration (Tmax)

    Tmax of MWN109.

    Time frame: From Day 1 to Day 29

  6. Elimination Half-Life (t1/2)

    t1/2 of MWN109.

    Time frame: From Day 1 to Day 29

Secondary outcomes

  1. Incidence of adverse events (AEs)

    The incidence of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: From Day 1 to Day 29

  2. Anti-Drug Antibody (ADA)

    ADA of MWN109.

    Time frame: From Day 1 to Day 29

07

Study locations

1 site
  • The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
    Kunming, Yunnan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Aug 2026, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 3, 2026
StartActual
May 24, 2026
Primary completionActual
Aug 10, 2026
CompletionActual
Aug 10, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07801326
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
May 24, 2026
Primary completion
Aug 10, 2026
Completion
Aug 10, 2026
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MWN109

Start the discussion